Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study

Omission of chemotherapy for low-grade, luminal A N1 breast cancer: Patterns of care and clinical outcomes

(2018) Waqar Haque et al.   BREAST

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer

(2018) Achim Wöckel et al.   GEBURTSHILFE UND FRAUENHEILKUNDE

Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer

(2016) Joachim Diessner et al.   BMC CANCER

If Chemotherapy Is Indicated, Give the Optimal Regimen!

(2016) Volker Möbus   Breast Care

Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study

(2016) W Janni et al.   BRITISH JOURNAL OF CANCER

Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study

(2016) Joachim Diessner et al.   PLoS One

Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study

(2015) J. Diessner et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

Is adjuvant chemotherapy omissible in women with T1–2 stage, node-positive, luminal A type breast cancer?

(2015) Hee Yong Kwak et al.   JOURNAL OF CHEMOTHERAPY

Histologic Grade Remains a Prognostic Factor for Breast Cancer Regardless of the Number of Positive Lymph Nodes and Tumor Size: A Study of 161 708 Cases of Breast Cancer From the SEER Program

(2014) Arnold M. Schwartz et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

(2014) Sylvia Adams et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response

(2013) E. H. Lips et al.   BREAST CANCER RESEARCH AND TREATMENT

Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial

(2013) Sandra M. Swain et al.   JOURNAL OF CLINICAL ONCOLOGY

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

(2012) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Adjuvant chemotherapy in luminal breast cancers

(2011) Elgene Lim et al.   BREAST

Breast Cancer Tumor Size, Nodal Status, and Prognosis: Biology Trumps Anatomy

(2011) Elizabeth A. Comen et al.   JOURNAL OF CLINICAL ONCOLOGY

Reproductive history and risk of three breast cancer subtypes defined by three biomarkers

(2010) Amanda I. Phipps et al.   CANCER CAUSES & CONTROL

A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer

(2010) T. O. Nielsen et al.   CLINICAL CANCER RESEARCH

Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study

(2010) Volker Moebus et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose-Dense Chemotherapy in Nonmetastatic Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials

(2010) L. Bonilla et al.   JNCI-Journal of the National Cancer Institute

Deconstructing the molecular portraits of breast cancer

(2010) Aleix Prat et al.   Molecular Oncology

Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial

(2009) Judith Hugh et al.   JOURNAL OF CLINICAL ONCOLOGY